8-K: Evolent Health Reports Q2 2026 Growth, Raises 2027 Outlook

Evolent Health announced second quarter 2026 results, showcasing significant revenue growth and providing an optimistic 2027 outlook with projected revenue increases exceeding 25%.

Summary

• Evolent Health reported strong revenue growth for the second quarter of 2026, reaching $652.5 million, a substantial increase from $444.3 million in the same period of 2025.
• The company reported a net loss attributable to common shareholders of $28.4 million for Q2 2026, an improvement from a net loss of $51.1 million in Q2 2025.
• Adjusted EBITDA for Q2 2026 was $28.1 million, down from $37.5 million in Q2 2025, with an Adjusted EBITDA margin of 4.3% compared to 8.5% in the prior year.
• Evolent is raising its full-year 2026 revenue guidance to $2.6 billion $2.7 billion and tightening its Adjusted EBITDA guidance to $120 million $135 million.
• The company anticipates over 25% revenue growth in 2027 compared to 2026, with an Adjusted EBITDA outlook at or above $150 million.
• Two new partnership announcements were made, including a significant Oncology Performance Suite partnership expected to generate approximately $300 million in annualized revenue, launching by December 2026.
• Total cash and cash equivalents stood at $115.7 million as of June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, with strong revenue growth and a positive outlook for 2027, but tempered by a net loss in the current quarter and ongoing industry headwinds.

Positives

• Revenue increased significantly by 46.8% to $652.5 million in Q2 2026 compared to $444.3 million in Q2 2025.
• Net loss attributable to common shareholders improved to $28.4 million in Q2 2026 from $51.1 million in Q2 2025.
• The company is raising its full-year 2026 revenue guidance to $2.6 billion $2.7 billion.
• The 2027 outlook projects revenue growth of over 25% compared to 2026.
• The 2027 Adjusted EBITDA outlook is expected to be at or above $150 million.
• A new Oncology Performance Suite partnership is expected to generate approximately $300 million in annualized revenue.
• Average PMPM fees for the Performance Suite increased to $24.05 from $13.76 in the prior year.
• Adjusted income per share improved to $0.02 in Q2 2026 from a loss of $(0.10) in Q2 2025.

Negatives

• Adjusted EBITDA decreased to $28.1 million in Q2 2026 from $37.5 million in Q2 2025.
• Adjusted EBITDA margin declined to 4.3% in Q2 2026 from 8.5% in Q2 2025.
• The Medical Expense Ratio (MER) increased significantly to 95.3% in Q2 2026 from 80.0% in Q2 2025.
• Average PMPM fees for Administrative Services decreased to $13.46 from $15.13 in the prior year.
• Total current liabilities increased to $492.8 million as of June 30, 2026, from $385.3 million as of December 31, 2025.
• Reserve for claims and performance-based arrangements more than doubled to $378.4 million from $192.2 million.

Risks

• Significant industry headwinds from Medicaid and other client-specific membership attrition are expected.
• The company faces risks related to the increasing number of risk-sharing arrangements.
• Failure by customers to provide accurate and timely information could impact operations.
• There is a risk of not recovering upfront costs in partner relationships.
• Competition could limit market share expansion.
• The company is subject to audits by CMS and other governmental payers.
• Evolution of the healthcare regulatory and political framework poses a risk.
• Data loss or corruption due to system failures or service disruptions is a concern.

Future Outlook

Evolent is raising its full-year 2026 revenue guidance to $2.6 billion to $2.7 billion and tightening its Adjusted EBITDA guidance to $120 million to $135 million. For 2027, the company expects revenue growth of over 25% compared to 2026, with Adjusted EBITDA at or above $150 million, driven by improved Performance Suite care margins and expense reductions, despite industry headwinds.

Management Comments

• "We believe our results for the second quarter of 2026, our updated 2026 guidance and our 2027 outlook all demonstrate that Evolent is delivering strong growth, profitability and cash flow."
• "We are confident in our emerging AI-led operational model that we believe allows us to deliver excellent client and clinical outcomes, while being highly disciplined with our cost structure."
• "Looking ahead to 2027, based on contracts in place today, upcoming launches scheduled and the strong continuing demand for our oncology solution, we expect to see revenue growth of over 25% compared to 2026."
• "We expect the midpoint of our 2027 Adjusted EBITDA outlook will be at or above $150 million driven by expected improved Performance Suite care margins and a strong focus on expense reductions, despite significant continued industry headwinds from Medicaid and other client specific membership attrition."
• "We also expect improved cash flow conversion, which, together with targeted debt reduction initiatives we are currently evaluating, we believe provides a clear path to addressing our capital structure and enhancing financial flexibility."

Industry Context

StockSavvy.ai notes that Evolent's focus on complex specialty care solutions, particularly in oncology, aligns with a growing trend in the healthcare industry where payers and providers seek specialized management to improve outcomes and control costs. The company's ability to secure large partnerships, like the $300 million annualized revenue oncology deal, highlights the demand for such integrated solutions.

Comparison to Industry Standards

• The reported revenue growth of 46.8% for Q2 2026 significantly outpaces the general healthcare IT and services sector growth rates, which typically range from single digits to low double digits.
• The projected 2027 revenue growth of over 25% indicates Evolent's strategy to capture market share in specialized healthcare management, a segment experiencing higher demand than broader healthcare services.
• The Adjusted EBITDA margin of 4.3% in Q2 2026 is lower than historical industry benchmarks for mature, profitable healthcare service companies, suggesting Evolent is in a growth phase with significant investment or facing margin pressures.
• The Medical Expense Ratio (MER) of 95.3% is notably high, indicating that a large portion of revenue is being consumed by medical costs, which is a concern compared to industry standards where efficient management aims for lower MERs, especially for non-provider-owned entities.

Legal Proceedings

• The filing mentions potential legal proceedings and government inquiries, reviews, audits, or investigations as a general risk factor.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong revenue growth and positive 2027 outlook, but tempered by current net loss and high Medical Expense Ratio.
• Creditors: The company's stated intention to evaluate debt reduction initiatives may be viewed positively, but the current debt levels and liabilities remain significant.
• Employees: Continued focus on an AI-led operational model and cost discipline may impact workforce dynamics.
• Customers/Partners: Expansion of services and new partnerships indicate continued demand for Evolent's solutions.

Next Steps

• Launch of the new Oncology Performance Suite partnership by December 2026, subject to regulatory approvals.
• Implementations for the expanded Specialty Technology & Services Suite agreement during the third and fourth quarters of 2026.
• Continue to evaluate targeted debt reduction initiatives.
• Focus on expense reductions to improve profitability.
• Continue to deploy cash for capitalized software development ($25 million to $30 million expected in 2026).

Key Dates

Recommendation

The company demonstrates strong revenue growth and a positive long-term outlook, particularly for 2027. However, the current quarter's net loss, declining Adjusted EBITDA margin, and a high Medical Expense Ratio warrant caution. The significant increase in liabilities related to claims and performance-based arrangements also presents a risk. Therefore, a 'hold' recommendation is appropriate, pending further clarity on margin improvement and cost management.

Keywords

Evolent Health, Healthcare Solutions, Performance Suite, Specialty Technology, Oncology, Medicaid, Medicare, Financial Results